Fred Alger Management’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $26.3M | Sell |
138,797
-629,957
| -82% | -$118M | 0.09% | 101 |
|
|
2026
Q1 | $151M | Buy |
768,754
+109,394
| +17% | +$21.1M | 0.66% | 24 |
|
|
2025
Q4 | $121M | Buy |
659,360
+631,861
| +2,298% | +$111M | 0.48% | 34 |
|
|
2025
Q3 | $4.22M | Sell |
27,499
-4,891
| -15% | -$740K | 0.02% | 259 |
|
|
2025
Q2 | $4.53M | Sell |
32,390
-66,723
| -67% | -$9.35M | 0.02% | 242 |
|
|
2025
Q1 | $14.6M | Buy |
99,113
+49,797
| +101% | +$7.2M | 0.08% | 138 |
|
|
2024
Q4 | $6.46M | Sell |
49,316
-129,491
| -72% | -$18.1M | 0.03% | 217 |
|
|
2024
Q3 | $27.9M | Buy |
178,807
+46,620
| +35% | +$7.53M | 0.14% | 113 |
|
|
2024
Q2 | $20.6M | Buy |
132,187
+102,005
| +338% | +$15.3M | 0.1% | 130 |
|
|
2024
Q1 | $4.09M | Buy |
30,182
+2,984
| +11% | +$395K | 0.02% | 274 |
|
|
2023
Q4 | $3.66M | Sell |
27,198
-420,163
| -94% | -$54.6M | 0.02% | 277 |
|
|
2023
Q3 | $60.6M | Sell |
447,361
-298,149
| -40% | -$40.7M | 0.35% | 80 |
|
|
2023
Q2 | $107M | Buy |
745,510
+188,782
| +34% | +$27.8M | 0.55% | 47 |
|
|
2023
Q1 | $77.3M | Sell |
556,728
-10,548
| -2% | -$1.42M | 0.41% | 72 |
|
|
2022
Q4 | $76.9M | Sell |
567,276
-51,020
| -8% | -$6.4M | 0.42% | 77 |
|
|
2022
Q3 | $67.8M | Sell |
618,296
-607,369
| -50% | -$77.1M | 0.34% | 82 |
|
|
2022
Q2 | $162M | Buy |
1,225,665
+476,544
| +64% | +$62.5M | 0.76% | 32 |
|
|
2022
Q1 | $99.4M | Buy |
749,121
+737,396
| +6,289% | +$88.4M | 0.32% | 104 |
|
|
2021
Q4 | $1.37M | Buy |
11,725
+353
| +3% | +$41.5K | ﹤0.01% | 380 |
|
|
2021
Q3 | $1.37M | Hold |
11,372
| – | – | ﹤0.01% | 367 |
|
|
2021
Q2 | $1.36M | Hold |
11,372
| – | – | ﹤0.01% | 375 |
|
|
2021
Q1 | $1.13M | Sell |
11,372
-23,097
| -67% | -$2.32M | ﹤0.01% | 373 |
|
|
2020
Q4 | $3.45M | Sell |
34,469
-36,106
| -51% | -$3.82M | 0.01% | 299 |
|
|
2020
Q3 | $7.74M | Sell |
70,575
-11,960
| -14% | -$1.33M | 0.02% | 217 |
|
|
2020
Q2 | $8.73M | Buy |
82,535
+10,112
| +14% | +$1.04M | 0.03% | 191 |
|
|
2020
Q1 | $6.47M | Sell |
72,423
-2,844
| -4% | -$268K | 0.03% | 196 |
|
|
2019
Q4 | $7.51M | Buy |
75,267
+2,500
| +3% | +$235K | 0.03% | 207 |
|
|
2019
Q3 | $6.49M | Buy |
72,767
+21,003
| +41% | +$1.82M | 0.03% | 202 |
|
|
2019
Q2 | $4.27M | Sell |
51,764
-8,878
| -15% | -$696K | 0.02% | 238 |
|
|
2019
Q1 | $4.9M | Buy |
60,642
+8,500
| +16% | +$670K | 0.02% | 222 |
|
|
2018
Q4 | $3.96M | Buy |
52,142
+10,438
| +25% | +$815K | 0.02% | 230 |
|
|
2018
Q3 | $3.3M | Buy |
41,704
+13,000
| +45% | +$983K | 0.01% | 256 |
|
|
2018
Q2 | $2.02M | Buy |
28,704
+274
| +1% | +$19.7K | 0.01% | 280 |
|
|
2018
Q1 | $1.99M | Buy |
28,430
+14,930
| +111% | +$1.03M | 0.01% | 295 |
|
|
2017
Q4 | $937K | Buy |
13,500
+1,500
| +13% | +$101K | ﹤0.01% | 340 |
|
|
2017
Q3 | $813K | Sell |
12,000
-19,000
| -61% | -$1.2M | ﹤0.01% | 333 |
|
|
2017
Q2 | $2.11M | Buy |
31,000
+1,000
| +3% | +$65.3K | 0.01% | 280 |
|
|
2017
Q1 | $1.87M | Buy |
30,000
+8,000
| +36% | +$466K | 0.01% | 292 |
|
|
2016
Q4 | $1.2M | Buy |
22,000
+13,000
| +144% | +$738K | 0.01% | 281 |
|
|
2016
Q3 | $591K | Buy |
+9,000
| New | +$588K | ﹤0.01% | 345 |
|
Other funds holding AZN
EP
IA
Fred Alger Management's AZN Position: Q2 2026 in Review
Fred Alger Management reduced its AstraZeneca (AZN) stake by 82% in Q2 2026, selling an estimated $118M and leaving 138,797 shares worth $26.3M. The position accounts for 0.09% of the portfolio, ranked #101.
Fred Alger Management first reported a position in AZN in Q3 2016 and has held it in 40 quarters since. The position peaked at $162M in Q2 2022. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Fred Alger Management held 138,797 shares of AstraZeneca worth $26.3M as of Q2 2026.
- Fred Alger Management sold 629,957 AstraZeneca shares in Q2 2026, an estimated $118M.
- AstraZeneca made up 0.09% of Fred Alger Management's portfolio in Q2 2026, its #101 holding.
- Fred Alger Management first reported a position in AstraZeneca in Q3 2016 and has held it in 40 quarters since.
- Fred Alger Management's AstraZeneca position peaked at $162M in Q2 2022.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Fred Alger Management's 13F filing for Q2 2026, filed 14 Aug 2026.